Semaglutide for Sale: Complete Research Guide — Mechanisms, Clinical Studies & GLP-1 Science
Shop Our Top Compounds
Semaglutide for Sale: Complete Semaglutide Research Guide — Mechanisms, Clinical Studies & GLP-1 Science
Semaglutide for Sale: Complete Research Guide — Mechanisms, Clinical Studies & GLP-1 Science
Semaglutide has emerged as one of the most extensively studied GLP-1 receptor agonists in modern biomedical research. Since its discovery at Novo Nordisk and subsequent investigation through more than a dozen landmark clinical trials, this peptide has generated an extraordinary body of published literature spanning metabolic science, cardiovascular research, hepatology, and neuroscience.
For researchers seeking semaglutide for sale as a reference compound or investigational tool, understanding the depth of published science behind this molecule is essential. This comprehensive guide examines the molecular design of semaglutide, its mechanism of action at the GLP-1 receptor, the full spectrum of clinical trial data from the SUSTAIN, STEP, and SELECT programs, its pharmacokinetic profile, comparisons with next-generation incretin peptides, and emerging research frontiers. All information presented here is derived from peer-reviewed, published studies and is intended for research purposes only.
Whether sourcing a semaglutide peptide for in vitro binding assays, receptor pharmacology studies, or analytical reference standards, this guide provides the scientific foundation researchers need. Explore our full catalog of GLP-1 receptor agonist peptides for additional research compounds.
What Is Semaglutide? Molecular Design and Structure
Discovery and Rational Design
Semaglutide is a long-acting analog of human glucagon-like peptide-1 (GLP-1), engineered through strategic amino acid substitutions and lipid conjugation to dramatically extend its half-life beyond that of native GLP-1, which is degraded within minutes in vivo. The molecule was developed through a rational medicinal chemistry approach described by Lau et al. (2015), building on the structural framework established by liraglutide.
The key structural modifications that define semaglutide include:
Amino acid substitution at position 8: Replacement of alanine with 2-aminoisobutyric acid (Aib), conferring resistance to dipeptidyl peptidase-4 (DPP-4) enzymatic cleavage — the primary degradation pathway for native GLP-1.
Amino acid substitution at position 34: Replacement of lysine with arginine, eliminating an alternative fatty acid acylation site to ensure uniform conjugation.
C-18 fatty diacid linker at position 26: A spacer-linked octadecandioic acid moiety attached to lysine-26, enabling high-affinity, non-covalent binding to serum albumin in circulation.
This molecular architecture results in a 31-amino acid peptide with 94% sequence homology to endogenous human GLP-1(7-37), preserving receptor binding affinity while extending the plasma half-life to approximately 165 hours (~7 days) — enabling once-weekly administration in research protocols.
Molecular Formula and Physical Properties
Semaglutide has a molecular weight of approximately 4,113.58 Da. Its molecular formula is C₁₈₇H₂₉₁N₄₅O₅₉. The peptide is water-soluble and typically supplied as a lyophilized powder for reconstitution in research settings. Researchers looking for high-purity semaglutide peptide for sale should verify quality assurance documentation, including HPLC purity data and mass spectrometry confirmation.
Mechanism of Action: How Semaglutide Activates the GLP-1 Receptor
GLP-1 Receptor Signaling Cascade
Semaglutide functions as a potent agonist at the glucagon-like peptide-1 receptor (GLP-1R), a class B1 G protein-coupled receptor (GPCR) expressed across multiple tissue types. Understanding GLP-1 receptor agonist research requires appreciation of the downstream signaling pathways activated upon receptor binding.
When semaglutide binds the GLP-1R, it triggers a conformational change that activates the stimulatory G protein (Gαs), initiating a signaling cascade:
Adenylyl cyclase activation → Increased intracellular cyclic AMP (cAMP)
Protein kinase A (PKA) activation → Phosphorylation of downstream targets
Exchange protein activated by cAMP (Epac2) engagement → Calcium-dependent exocytosis
β-arrestin recruitment → Receptor internalization and secondary signaling
In pancreatic beta cells, this cascade potentiates glucose-dependent insulin secretion — a critical distinction from sulfonylureas that stimulate insulin release regardless of glucose levels. Semaglutide also suppresses glucagon secretion from alpha cells, slows gastric emptying, and acts on hypothalamic GLP-1 receptors to modulate appetite signaling.
Central Nervous System Effects
GLP-1 receptors are expressed throughout the central nervous system, including the hypothalamus, brainstem (nucleus tractus solitarius), hippocampus, and cortex. Semaglutide research has demonstrated that the molecule crosses the blood-brain barrier and engages central appetite-regulatory circuits, particularly within the arcuate nucleus and paraventricular nucleus of the hypothalamus. Published research suggests effects on both homeostatic (energy balance) and hedonic (reward-driven) eating pathways, which has opened significant new avenues for neuroscience investigation.
Tissue Distribution of GLP-1 Receptors
The widespread expression of GLP-1R accounts for the multi-organ research interest in semaglutide:
Tissue | GLP-1R Expression | Research Focus |
|---|---|---|
Pancreatic beta cells | High | Insulin secretion, beta cell proliferation |
Hypothalamus | Moderate-High | Appetite regulation, energy homeostasis |
Heart/vasculature | Moderate | Cardiovascular protection, endothelial function |
Liver | Low-Moderate | Hepatic steatosis, lipid metabolism |
Kidney | Moderate | Renal hemodynamics, natriuresis, renal function monitoring |
GI tract | High | Gastric emptying, gut motility |
For more detail on GLP-1 receptor biology and related compounds, see our GLP-1 Receptor Agonist Peptides Guide and the Peptide Glossary.
Landmark Clinical Studies: SUSTAIN, STEP, and SELECT Trial Programs
The clinical evidence base for semaglutide is among the most robust for any peptide compound, encompassing multiple large-scale, randomized clinical trials, including phase 3 trials with rigorous control groups. These studies have been pivotal in establishing semaglutide’s efficacy and safety for various indications. Regulatory agencies such as the European Medicines Agency, alongside the FDA and Health Canada, have reviewed and approved semaglutide for specific uses based on this evidence. Below is a detailed review of the major trial programs. All dosing information reflects published study protocols and is presented for research reference only — not as guidance for human use.
SUSTAIN Trials: Glycemic Control Research
The SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) program comprised a series of trials evaluating subcutaneous semaglutide in subjects with type 2 diabetes.
SUSTAIN-6 stands as a particularly significant cardiovascular outcomes trial. In this study, Marso et al. (2016) randomly assigned 3,297 participants with type 2 diabetes and high cardiovascular risk to receive once-weekly semaglutide (0.5 mg or 1.0 mg) or placebo for 104 weeks. The primary composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke occurred in 6.6% of semaglutide-treated subjects versus 8.9% on placebo — representing a statistically significant 26% relative risk reduction (HR 0.74; 95% CI, 0.58–0.95; P<0.001 for noninferiority).
This trial established the cardiovascular safety profile of semaglutide and suggested potential cardioprotective properties that would be explored further in subsequent research programs.
STEP Trials: Body Weight Research
The STEP (Semaglutide Treatment Effect in People with Obesity) program investigated higher-dose semaglutide (2.4 mg weekly) specifically in the context of body weight research.
STEP 1 — Wilding et al. (2021) enrolled 1,961 adults with BMI ≥30 (or ≥27 with comorbidities) without diabetes. In published results, researchers administered semaglutide 2.4 mg subcutaneously once weekly for 68 weeks alongside lifestyle intervention. The semaglutide group demonstrated a mean body weight reduction of −14.9% versus −2.4% in the placebo group. Notably, 86.4% of participants in the semaglutide group achieved ≥5% weight loss, and 50.5% achieved ≥15% weight loss.
STEP 2 — Davies et al. (2021) evaluated semaglutide 2.4 mg in 1,210 adults with overweight/obesity and type 2 diabetes. Published data showed mean weight reductions of −9.6% with semaglutide 2.4 mg versus −3.4% with placebo at 68 weeks, demonstrating efficacy in a population where weight loss is historically more difficult to achieve.
STEP 5 — Garvey et al. (2022) extended the observation period to 104 weeks (2 years), providing critical long-term data. Published findings showed sustained mean weight loss of −15.2% with semaglutide 2.4 mg versus −2.6% with placebo at two years, demonstrating that the effects observed in shorter trials were maintained with continued administration.
SELECT Trial: Cardiovascular Outcomes in Obesity
The SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial represents a landmark in the field. Lincoff et al. (2023) enrolled 17,604 adults aged ≥45 with established cardiovascular disease and BMI ≥27, but without diabetes.
In this double-blind, placebo-controlled trial, researchers administered semaglutide 2.4 mg once weekly for a mean follow-up of 39.8 months. The primary endpoint — a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke — occurred in 6.5% of the semaglutide group versus 8.0% of the placebo group, representing a 20% relative risk reduction (HR 0.80; 95% CI, 0.72–0.90; P<0.001).
SELECT was the first cardiovascular outcomes trial to demonstrate that a GLP-1 receptor agonist reduces major adverse cardiovascular events (MACE) in people with obesity independent of diabetes status — a finding with profound implications for cardiovascular research.
Semaglutide Formulations: Injectable, Oral, and Research-Grade Variants
Semaglutide is available in multiple formulations, each tailored to specific research and clinical objectives in the fields of chronic weight management, obesity management, and cardiovascular disease prevention. The diversity of these formulations has expanded the scope of semaglutide research and enabled a broader range of clinical trials targeting weight management and metabolic health.
Injectable Semaglutide:The subcutaneous injectable form of semaglutide is the most widely studied and utilized in both clinical and research settings. Marketed under the brand names Ozempic and Wegovy, this formulation is administered once weekly and has become a cornerstone in chronic weight management protocols. Ozempic is primarily indicated for glycemic control in type 2 diabetes, while Wegovy is approved for adults with obesity or overweight who have at least one weight-related comorbidity, such as high blood pressure or dyslipidemia. The injectable formulation has been central to major clinical trials investigating not only weight loss and obesity management but also the reduction of major adverse cardiovascular events in populations at elevated cardiovascular risk.
Oral Semaglutide:The oral formulation, known as Rybelsus, represents a significant advancement in peptide drug delivery. Designed for daily administration, oral semaglutide utilizes an absorption enhancer to facilitate gastrointestinal uptake, making it the first GLP-1 receptor agonist available in tablet form. While currently approved for the treatment of type 2 diabetes, ongoing clinical trials are exploring its potential in weight management and obesity research. The oral formulation offers a convenient alternative for subjects who may prefer tablets over injections, broadening the accessibility of GLP-1–based therapies in both research and clinical practice.
Research-Grade Variants:Beyond commercial products, research-grade semaglutide is available for laboratory and investigational use. These high-purity peptides are essential for preclinical studies, mechanistic research, and early-phase clinical trials assessing new indications such as cardiovascular disease prevention and advanced obesity management strategies. Research-grade variants are supplied with comprehensive documentation, including quality assurance documentation and purity reports, ensuring reproducibility and reliability in experimental protocols. Iron Peak Peptides specializes in providing research-grade semaglutide and other GLP-1 receptor agonists to support the evolving needs of the scientific community.
The availability of injectable, oral, and research-grade semaglutide formulations continues to drive innovation in weight management, metabolic research, and cardiovascular disease prevention, enabling researchers to tailor their approach to the specific requirements of each study.
Pharmacokinetics and Pharmacodynamics
Absorption and Distribution
Understanding the pharmacokinetic profile of semaglutide is essential for researchers designing study protocols. Published pharmacokinetic analyses have established the following parameters:
Bioavailability (subcutaneous): ~89%
Time to maximum concentration (Tmax): 1–3 days post-injection
Volume of distribution: ~12.5 L (indicating primarily plasma/extracellular distribution)
Plasma protein binding: >99% (predominantly albumin-bound)
The high albumin binding is central to semaglutide’s extended half-life. The C-18 fatty diacid side chain enables reversible, non-covalent binding to the fatty acid binding sites on serum albumin, creating a circulating depot that gradually releases free peptide for receptor engagement.
Metabolism and Elimination
Half-life: ~165 hours (~7 days), supporting once-weekly dosing in research protocols
Metabolism: Proteolytic cleavage and beta-oxidation of the fatty acid side chain
Elimination: Primarily via urine (~3%) and feces (~5%) as metabolites; minimal intact peptide excretion
Steady-state: Achieved after 4–5 weekly administrations
Oral Formulation Pharmacokinetics
A unique aspect of semaglutide research is the development of an oral formulation co-formulated with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). The PIONEER trial program (Husain et al., 2019) demonstrated that oral semaglutide achieved cardiovascular noninferiority versus placebo, though oral bioavailability is significantly lower (~1%) compared to subcutaneous delivery, requiring higher doses. This oral delivery approach remains an active area of peptide delivery research.
Anti-Inflammatory and Cardioprotective Mechanisms
Beyond Weight Reduction: Multi-Pathway Cardiovascular Effects
One of the most active areas of semaglutide research involves the mechanisms underlying its observed cardiovascular benefits. Published evidence suggests these effects extend well beyond weight reduction alone.
Verma et al. (2022) conducted a pooled analysis of STEP program data examining the effects of semaglutide 2.4 mg on C-reactive protein (CRP), a validated biomarker of systemic inflammation and cardiovascular risk. The analysis demonstrated significant reductions in CRP with semaglutide treatment, with greater proportions of semaglutide-treated subjects shifting to lower cardiovascular risk categories as defined by CRP thresholds.
Mosenzon et al. (2022) further analyzed high-sensitivity CRP (hsCRP) data across the SUSTAIN and PIONEER programs, reporting consistent reductions in inflammatory biomarkers with semaglutide versus comparators in subjects with type 2 diabetes. A comprehensive meta-analysis by Masson et al. (2024) synthesized available evidence and concluded that semaglutide demonstrates significant anti-inflammatory effects across multiple populations, irrespective of glycemic status.
These findings suggest that GLP-1 receptor activation may influence cardiovascular outcomes through:
Reduction of systemic inflammation (CRP, IL-6, TNF-α)
Improvement in endothelial function and vascular reactivity
Reduction in atherogenic lipid profiles (triglycerides, VLDL)
Direct effects on cardiomyocyte GLP-1 receptors
Reduction of oxidative stress in vascular tissue
Research on Hepatic Steatosis and NASH
Semaglutide has been investigated for its effects on nonalcoholic steatohepatitis (NASH), now reclassified as metabolic dysfunction-associated steatohepatitis (MASH). In a phase 2 trial, Newsome et al. (2021) randomized 320 patients with biopsy-confirmed NASH to subcutaneous semaglutide (0.1, 0.2, or 0.4 mg daily) or placebo for 72 weeks. Major clinical trials have also confirmed semaglutide’s efficacy in treating fatty liver disease, chronic kidney disease, and heart failure.
Published results demonstrated that 59% of subjects receiving semaglutide 0.4 mg achieved NASH resolution (defined by histological criteria) versus 17% on placebo (P< 0.001). While fibrosis improvement did not reach statistical significance in this trial, the histological improvements in steatosis and inflammation were substantial, prompting ongoing phase 3 investigation.
These findings are relevant for researchers studying the intersection of GLP-1 receptor signaling, hepatic lipid metabolism, and inflammatory liver pathology. In NASH research, metabolic markers such as total cholesterol, LDL, HDL, triglycerides, and free fatty acids are commonly assessed to evaluate the impact of semaglutide on hepatic and metabolic health. The observation that GLP-1R activation can reverse hepatic steatohepatitis histologically opens important translational research questions.
Semaglutide vs. Tirzepatide vs. Retatrutide: Comparative GLP-1 Research
Tirzepatide: Dual GIP/GLP-1 Receptor Agonism
The development of multi-receptor incretin agonists represents the next frontier in this research area. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist that has been directly compared to semaglutide in published research.
In the SURMOUNT-1 trial, Jastreboff et al. (2022) demonstrated that tirzepatide at the highest dose (15 mg weekly) produced mean weight reductions of −20.9% versus −3.1% with placebo over 72 weeks in adults with obesity — numerically exceeding the −14.9% observed in STEP 1 with semaglutide 2.4 mg, though cross-trial comparisons have inherent limitations.
A real-world comparative analysis by Rodriguez et al. (2024) published in JAMA Internal Medicine provided head-to-head data, finding that tirzepatide was associated with significantly greater weight reduction compared to semaglutide (−5.9% vs. −3.6% additional body weight over 3–6 months; HR for ≥5% weight loss: 1.76). These comparative data are valuable for researchers evaluating the incremental effects of dual versus single receptor agonism.
Researchers interested in comparative studies can source both compounds from IronPeak’s catalog: Shop Semaglutide | Shop Tirzepatide
Retatrutide: Triple GIP/GLP-1/Glucagon Receptor Agonism
Retatrutide represents the newest generation of multi-agonist peptides, acting simultaneously at GIP, GLP-1, and glucagon receptors. In a phase 2 trial, Jastreboff et al. (2023) reported that retatrutide at the highest dose (12 mg weekly) produced unprecedented mean weight reductions of −24.2% over 48 weeks in adults with obesity — with 63% of participants achieving ≥20% weight loss.
Rosenstock et al. (2023) further evaluated retatrutide in subjects with type 2 diabetes, demonstrating robust improvements in both glycemic control and body weight that exceeded published results for single and dual agonists.
The triple-agonist mechanism adds glucagon receptor activation, which is hypothesized to increase energy expenditure through hepatic and adipose tissue metabolic pathways — a mechanistic distinction from semaglutide and tirzepatide that is driving significant preclinical and translational research interest.
Comparative Summary Table
For a deeper exploration of peptides studied for body composition, see our guide on Peptides for Fat Loss Research.
Emerging Research Frontiers
Neuroprotection and Cognitive Research
GLP-1 receptor agonists including semaglutide are under active investigation for neuroprotective properties. Published preclinical research has demonstrated that GLP-1R activation reduces neuroinflammation, enhances synaptic plasticity, and attenuates amyloid-beta pathology in animal models. Multiple clinical trials are currently evaluating semaglutide in neurodegenerative disease contexts, representing one of the most watched emerging research areas for this peptide class.
Kidney and Renal Research
Published data from cardiovascular outcomes trials have demonstrated improvements in renal endpoints in patients with chronic kidney disease and kidney disease, including reductions in albuminuria and slower estimated GFR decline. Major clinical trials have confirmed semaglutide’s efficacy in treating chronic kidney disease, as well as fatty liver disease and heart failure. Dedicated renal outcomes trials with semaglutide are ongoing and represent an important expansion of the research landscape.
Addiction and Behavioral Research
An unexpected and rapidly growing research area involves the effects of GLP-1R agonists on reward circuitry and addictive behaviors. Preclinical and observational studies have reported associations between GLP-1R agonist use and reduced consumption of alcohol, nicotine, and other substances — findings attributed to modulation of mesolimbic dopamine signaling through central GLP-1 receptors.
Research Applications and Laboratory Considerations
In Vitro Receptor Binding and Functional Assays
Semaglutide serves as a critical reference compound in GLP-1 receptor pharmacology research. Common laboratory applications include competitive radioligand binding assays to determine receptor affinity (Ki values), cAMP accumulation assays to measure functional potency (EC50), and β-arrestin recruitment assays to characterize signaling bias. Researchers frequently compare semaglutide’s pharmacological profile against native GLP-1(7-36)amide, exendin-4, liraglutide, and newer multi-agonist peptides to establish structure-activity relationships.
Stability and Handling for Research Use
For researchers sourcing semaglutide where to buy for laboratory investigation, proper handling is essential for experimental reproducibility. Lyophilized semaglutide peptide should be stored at −20°C and protected from light and moisture. Upon reconstitution in sterile water or appropriate buffer, aliquots should be stored at −80°C for long-term stability. Repeated freeze-thaw cycles should be minimized. The high albumin-binding affinity of semaglutide means that in vitro assay systems containing serum proteins may exhibit different free-peptide concentrations than serum-free systems — an important consideration for dose-response characterization.
Analytical Reference Standards
High-purity semaglutide is also used as an analytical reference standard for mass spectrometry method development, HPLC method validation, and quality control testing. Researchers should verify supplier quality assurance confirming ≥95% purity by HPLC, correct molecular weight by LC-MS, and appropriate peptide content by amino acid analysis. Iron Peak Peptides provides comprehensive analytical documentation with every semaglutide research peptide order.
Frequently Asked Questions
What is semaglutide used for in research?
Semaglutide is used as a reference compound and investigational tool in GLP-1 receptor agonist research. Published studies have investigated its effects on metabolic signaling, cardiovascular biomarkers, hepatic steatosis models, neuroinflammation, and appetite-regulatory pathways. It serves as a benchmark comparator for evaluating next-generation incretin peptides including tirzepatide and retatrutide. All research use should comply with applicable regulations. For research purposes only.
How does semaglutide work at the molecular level?
Semaglutide binds to and activates the GLP-1 receptor, a class B1 GPCR, initiating intracellular signaling through the cAMP/PKA pathway. Its structural modifications — including an Aib substitution at position 8 and a C-18 fatty diacid conjugation — confer DPP-4 resistance and high albumin binding, extending its half-life to approximately 7 days. This enables sustained receptor activation compared to native GLP-1, which has a half-life of only 2–3 minutes.
What is the difference between semaglutide and tirzepatide in research?
Semaglutide is a selective GLP-1 receptor agonist, while tirzepatide is a dual GIP/GLP-1 receptor agonist. Published comparative research suggests tirzepatide produces greater weight reduction and glycemic improvement, likely due to additive signaling through the GIP receptor. However, semaglutide has more extensive long-term cardiovascular outcomes data (SELECT trial). Both are available as research peptides from Iron Peak Peptides.
Where can researchers buy semaglutide online?
Researchers looking to buy semaglutide online for legitimate research applications can source high-purity semaglutide peptide from Iron Peak Peptides. All products include quality assurance with HPLC purity verification and mass spectrometry data. Semaglutide is sold strictly as a research chemical — not for human consumption.
What were the key findings of the STEP clinical trials?
The STEP trial program demonstrated that in published studies, researchers administered semaglutide 2.4 mg subcutaneously once weekly and observed mean body weight reductions of 14.9% (STEP 1), 9.6% in subjects with type 2 diabetes (STEP 2), and sustained 15.2% reduction over two years (STEP 5). These peer-reviewed findings established semaglutide as the most extensively studied GLP-1 receptor agonist for body weight research.
What is the pharmacokinetic half-life of semaglutide?
Published pharmacokinetic analyses report a terminal elimination half-life of approximately 165 hours (~7 days) for subcutaneous semaglutide. This extended half-life is primarily attributable to its high-affinity albumin binding via the C-18 fatty diacid side chain. Steady-state plasma concentrations are achieved after approximately 4–5 weekly administrations in research protocols.
How does semaglutide compare to retatrutide?
Semaglutide targets only the GLP-1 receptor, while retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. In published phase 2 data, retatrutide produced greater weight reduction (up to −24.2%) compared to semaglutide (~15%), though retatrutide lacks the long-term cardiovascular outcomes data available for semaglutide. Both peptides are available for research from Iron Peak Peptides.
Is semaglutide available for research purchase?
Yes. Researchers can find semaglutide for sale as a research-grade peptide at Iron Peak Peptides. All products are manufactured under strict quality control, supplied with full analytical documentation, and sold exclusively for in vitro research and analytical reference use. Semaglutide is not for human consumption.
Conclusion
Semaglutide stands as one of the most thoroughly validated peptide compounds in modern research, supported by an evidence base of over a dozen large-scale clinical trials, hundreds of peer-reviewed publications, and ongoing investigation across metabolic, cardiovascular, hepatological, and neuroscience domains. From the foundational SUSTAIN trials establishing cardiovascular safety to the transformative STEP program demonstrating robust weight-related effects, and the landmark SELECT trial proving MACE reduction independent of diabetes — the scientific record for this GLP-1 receptor agonist is unmatched in its depth.
Clinical trials consistently show that initial weight loss with semaglutide is significant, and long-term weight management requires ongoing therapy to maintain weight loss and prevent weight regain. Weight loss maintenance remains a key challenge in obesity research, as weight regain is common after initial interventions; however, sustained treatment with semaglutide has demonstrated minimal weight regain over extended periods.
For researchers exploring incretin biology, the comparative landscape now includes single (semaglutide), dual (tirzepatide), and triple (retatrutide) receptor agonists — creating unprecedented opportunities for mechanistic and translational investigation.
Researchers seeking high-purity semaglutide peptide for sale can explore Iron Peak Peptides’ semaglutide product page and browse the full GLP-1 research peptide catalog. For related research compounds, see our guides on peptides for fat loss research and the Peptide Glossary.
Research References
Lau J, et al. “Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.” Journal of Medicinal Chemistry, 58(18), 7370–7380, 2015. DOI: 10.1021/acs.jmedchem.5b00726
Knudsen LB, Lau J. “The Discovery and Development of Liraglutide and Semaglutide.” Frontiers in Endocrinology, 10:155, 2019. DOI: 10.3389/fendo.2019.00155
Marso SP, et al. “Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.” New England Journal of Medicine, 375(19), 1834–1844, 2016. DOI: 10.1056/NEJMoa1607141
Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 384(11), 989–1002, 2021. DOI: 10.1056/NEJMoa2032183
Davies M, et al. “Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2).” The Lancet, 397(10278), 971–984, 2021. DOI: 10.1016/S0140-6736(21)00213-0
Garvey WT, et al. “Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.” Nature Medicine, 28, 2083–2091, 2022. DOI: 10.1038/s41591-022-02026-4
Lincoff AM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” New England Journal of Medicine, 389(24), 2221–2232, 2023. DOI: 10.1056/NEJMoa2307563
Husain M, et al. “Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.” New England Journal of Medicine, 381(9), 841–851, 2019. DOI: 10.1056/NEJMoa1901118
Newsome PN, et al. “A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.” New England Journal of Medicine, 384(12), 1113–1124, 2021. DOI: 10.1056/NEJMoa2028395
Verma S, et al. “Effects of once-weekly semaglutide 2.4 mg on C-reactive protein: a STEP program analysis.” Cardiovascular Diabetology, 21, 272, 2022. DOI: 10.1186/s12933-022-01686-z
Mosenzon O, et al. “Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER trials.” Diabetes, Obesity and Metabolism, 24(11), 2129–2140, 2022. DOI: 10.1111/dom.14841
Masson W, et al. “Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis.” Expert Review of Clinical Pharmacology, 17(7), 627–639, 2024. DOI: 10.1080/17512433.2024.2384170
Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, 387(4), 327–340, 2022. DOI: 10.1056/NEJMoa2206038
Rodriguez PJ, et al. “Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.” JAMA Internal Medicine, 184(9), 1056–1064, 2024. DOI: 10.1001/jamainternmed.2024.2525
Jastreboff AM, et al. “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” New England Journal of Medicine, 389(6), 514–526, 2023. DOI: 10.1056/NEJMoa2301972
Rosenstock J, et al. “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator-controlled, parallel-group, phase 2 trial.” The Lancet, 402(10401), 529–544, 2023. DOI: 10.1016/S0140-6736(23)01053-X
Mahapatra MK, et al. “Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes.” Reviews in Endocrine and Metabolic Disorders, 23, 521–539, 2022. DOI: 10.1007/s11154-021-09699-1
Weghuber D, et al. “Once-Weekly Semaglutide in Adolescents with Obesity.” New England Journal of Medicine, 387(24), 2245–2257, 2022. DOI: 10.1056/NEJMoa2208601
Research Disclaimer
All content in this article is presented for educational and informational purposes in the context of scientific research. The information provided is derived from peer-reviewed, published literature and does not constitute medical advice, diagnosis, or treatment recommendations. Semaglutide and all peptide products sold by Iron Peak Peptides are intended for laboratory research and in vitro study only. These products are not for human consumption and are not intended to diagnose, treat, cure, or prevent any disease. All research involving peptide compounds must comply with applicable federal, state, and institutional regulations. Consult published literature and institutional review boards for research protocol guidance. For research purposes only.
Related Research
🔬 Explore Research Peptides
- SS-31 10mg — $89.00
- BPC-157 10mg — $60.00
- Melanotan 1 10mg — $44.00
- LL-37 5mg — $69.00
